News & Updates

Show Multimedia Only
Osilodrostat curbs hypercortisolism in most patients with adrenal CS Osilodrostat curbs hypercortisolism in most patients with adrenal CS

Osilodrostat curbs hypercortisolism in most patients with adrenal CS

29 Jul 2026 byStephen Padilla

Use of osilodrostat is effective at controlling hypercortisolism in one of three (66.7 percent) patients with adrenal Cushing's syndrome (CS) treated for longer than 4 weeks and in nearly four of five (87.5 percent) individuals treated for more than 12 weeks, a real-world study has shown. It also displays a positive impact on blood pressure and body weight.

29 Jul 2026
Which anti-obesity drug is safest, most effective?

Which anti-obesity drug is safest, most effective?

27 Jul 2026 byStephen Padilla

Among available drugs for obesity, tirzepatide and cagrilintide-semaglutide (CagriSema) yield the largest decrease in body weight, regardless of diabetes status, suggest the results of a systematic review and network meta-analysis.

27 Jul 2026
Steroid safety made simple with the new MOH Steroid Card

Steroid safety made simple with the new MOH Steroid Card

22 Jul 2026 bySaras Ramiya, Senior Editor, MPF

A standardised steroid card is now available after years of effort by a team of endocrinologists and pharmacists from the Ministry of Health (MOH).

22 Jul 2026